Tissue Regenix Group Regulatory News (TRX)

Tissue Regenix Group plc

Change of registered office

Leeds, 29 October 2020 - Tissue Regenix Group (AIM:TRX) the regenerative medical devices company announces that the Company's registered office and UK manufacturing facility has changed with immediate effect from Unit 1 & 2, Astley Way, Astley Lane Industrial Estate, Swillington, LS26 8XT to: Unit 3, Phoenix Court, Lotherton Way, Garforth, LS25 2GY.

The decision to undertake this move was initially announced in August, as part of ongoing overhead cost reduction initiatives, and it is expected to deliver savings of over £0.4m on an annualised basis from 2021. 

For more Information:

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds, UK. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.

In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.', January 2016 saw the establishment of joint venture GBM-V, a multi- tissue bank based in Rostock, Germany.

In August 2017 Tissue Regenix acquired CellRight Technologies®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopaedic, foot & ankle, dental, and sports medicine surgical procedures.